Direct costs of severe cutaneous adverse reactions in a tertiary hospital in Korea
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: There are only a few reports on the direct costs of severe cutaneous adverse reactions (SCARs), including drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), despite the tremendous negative impact these reactions can have on patients. We estimated the direct costs of treating SCARs. Methods: Patients admitted to a tertiary teaching hospital for the treatment of SCARs from January 1, 2005 to December 31, 2010 were included. Patients who had experienced SCARs during their admission for other medical conditions were excluded. The direct costs of hospitalization and outpatient department visits were collected. Inpatient and outpatient care costs were calculated, and factors affecting inpatient care costs were analyzed. Results: The total healthcare cost for the management of 73 SCAR patients (36 with DRESS, 21 with SJS, and 16 with TEN) was 752,067 US dollars (USD). Most of the costs were spent on inpatient care (703,832 USD). The median inpatient care cost per person was 3,720 (range, 1,133 to 107,490) USD for DRESS, 4,457 (range, 1,224 to 21,428) USD for SJS, and 8,061 (range, 1,127 to 52,220) USD for TEN. Longer hospitalization significantly increased the inpatient care costs of the patients with DRESS (by 428 USD [range, 395 to 461] per day). Longer hospitalization and death significantly increased the inpatient care costs of the patients with SJS/TEN (179 USD [range, 148 to 210] per day and an additional 14,425 USD [range, 9,513 to 19,337] for the deceased). Conclusions: The management of SCARs required considerable direct medical costs. SCARs are not only a health problem but also a significant financial burden for the affected individuals.
Abstract
Background/Aims: There are only a few reports on the direct costs of severe cutaneous adverse reactions (SCARs), including drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), despite the tremendous negative impact these reactions can have on patients. We estimated the direct costs of treating SCARs. Methods: Patients admitted to a tertiary teaching hospital for the treatment of SCARs from January 1, 2005 to December 31, 2010 were included. Patients who had experienced SCARs during their admission for other medical conditions were excluded. The direct costs of hospitalization and outpatient department visits were collected. Inpatient and outpatient care costs were calculated, and factors affecting inpatient care costs were analyzed. Results: The total healthcare cost for the management of 73 SCAR patients (36 with DRESS, 21 with SJS, and 16 with TEN) was 752,067 US dollars (USD). Most of the costs were spent on inpatient care (703,832 USD). The median inpatient care cost per person was 3,720 (range, 1,133 to 107,490) USD for DRESS, 4,457 (range, 1,224 to 21,428) USD for SJS, and 8,061 (range, 1,127 to 52,220) USD for TEN. Longer hospitalization significantly increased the inpatient care costs of the patients with DRESS (by 428 USD [range, 395 to 461] per day). Longer hospitalization and death significantly increased the inpatient care costs of the patients with SJS/TEN (179 USD [range, 148 to 210] per day and an additional 14,425 USD [range, 9,513 to 19,337] for the deceased). Conclusions: The management of SCARs required considerable direct medical costs. SCARs are not only a health problem but also a significant financial burden for the affected individuals.
참고문헌 (12)
- International Drug Monitoring : the Role of National Centers, "World Health Organization", WHO, ~ (1972)
- Lazarou J, "Incidence of adverse drug reactions in hospitalized patients : a meta-analysis of prospective studies", JAMA, 279, pp.1200~1205 (1998)
- Bates DW, "The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group", JAMA, 277, pp.307~311 (1997)
- Izquierdo E, "Determination of the frequency and direct cost of the adverse drug events in Argentina", Curr Drug Saf, 4, pp.103~106 (2009)
- Bordet R, "Analysis of the direct cost of adverse drug reactions in hospitalised patients", Eur J Clin Pharmacol, 56, pp.935~941 (2001)
- Gautier S, "The cost of adverse drug reactions", Expert Opin Pharmacother, 4, pp.319~326 (2003)
- Barvaliya M, "Drug-induced Stevens-Johnson syndrome(SJS), toxic epidermal necrolysis(TEN), and SJS-TEN overlap : a multicentric retrospective study", J Postgrad Med, 57, pp.115~119 (2011)
- Yang MS, "Clinical features and prognostic factors in severe cutaneous drug reactions", Int Arch Allergy Immunol, 162, pp.346~354 (2013)
- Bastuji-Garin S, "Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme", Arch Dermatol, 129, pp.92~96 (1993)
- Kardaun SH, "Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?", Br J Dermatol, 156, pp.609~611 (2007)
- Schlienger RG, "Quantifying the costs of serious adverse drug reactions to antiepileptic drugs", Epilepsia, (39 Suppl 7), pp.S27~S32 (1998)
- "Expenditure on health" (2017)[URL]